Theravance Seeks A Way Back From Second Ampreloxetine Disappointment
With New MSA Focus
Executive Summary
The US firm’s ampreloxetine flunked a second Phase III orthostatic hypotension study but positive data in a prespecified subset have left a narrow path for a potential collaboration and approval, its CEO tells Scrip.
You may also be interested in...
Finance Watch: Theravance Eliminates Debt In $1.1bn Trelegy Royalty Sell-Off
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
Innoviva Aims For Antibiotic Success With La Jolla, Entasis Acquisitions
Having recently bought antibacterial developer Entasis, Innoviva adds approved antibiotic Xerava and hypotension drug Giapreza to its portfolio along with La Jolla’s established commercial organization.
Theravance To Slash Headcount By 75% After Latest Clinical Trial Setback
The Phase III failure of ampreloxetine in nOH followed disappointing Phase IIb data for izencitinib in ulcerative colitis in August. Theravance narrows focus to respiratory disease, including label expansions for Yupelri.